Your Navigation:PCAR > Abstract
Search pcar
检索项:
检索词:
Abstract
Pharmaceutical Care and Research: 2019; 19(4):259-262,294
DOI: 10.5428/pcar20190406
Efficacy of dual anti-platelet therapy with ticagrelor and aspirin in the treatment of acute myocardial infarction patients undergoing percutaneous coronary intervention
1. ZHANG Jiangxia1(1.Department of Pharmacy,Nanshi Hospital of Nanyang City,Henan Province,Henan Nanyang 473000,China zjxia2013@163.com)
2. DING Yanhua1(1.Department of Pharmacy,Nanshi Hospital of Nanyang City,Henan Province,Henan Nanyang 473000,China dyh_1107@126.com)
3. LI Xianzhe2(2.Department of Cardiovasology,Nanshi Hospital of Nanyang City,Henan Province,Henan Nanyang 473000,China )
4. LUO Yamin2(2.Department of Cardiovasology,Nanshi Hospital of Nanyang City,Henan Province,Henan Nanyang 473000,China )
5. ZHANG Jing1(1.Department of Pharmacy,Nanshi Hospital of Nanyang City,Henan Province,Henan Nanyang 473000,China )
ABSTRACT  Objective: To investigate the efficacy,prognosis and safety of ticagrelor and aspirin in the treatment of acute myocardial infarction(AMI) patients undergoing percutaneous coronary intervention(PCI).Methods: One hundred and three AMI patients with an age of 40-85 years were recruited for the study and were randomly divided into observation group (n=53) and control group (n=50). The observation group was given anti-platelet therapy with ticagrelor and aspirin, and the control group received treatment with clopidogrel and aspirin. Then, myocardial reperfusion after surgery was compared between the two groups. Cardiac color Doppler ultrasonography was performed before and 3 months after surgery. The left heart function (left ventricular ejection function (LVEF) and left ventricular end diastolic diameter (LVEDD)) were compared between the two groups. The incidence of major adverse cardiovascular events (MACE) during the follow-up period was also compared.The levels of creatine kinase isoenzyme(CK-MB),hypersensitive C-reactive protein(hs-CRP),IL-8,TNF-α and other inflammatory factors were all compared before and after treatment to evaluate the efficacy and prognosis.The incidence of bleeding during the 3-month follow-up in the two groups was compared to evaluate safety.Results: In patients with AMI-PCI,ticagrelor was beneficial for myocardial reperfusion (percentage of patients with TIMI Ⅲ was 90.57% vs 100%).Ticagrelor could significantly improve left ventricular function (LVEF:P=0.004,LVEDD:P=0.000),reduce the incidence of MACE (7.69% vs 0%,P=0.048),improve myocardial injury(CK-MB:P=0.004),effectively control inflammatory reactions (hs-CRP:P=0.035,IL-8:P=0.000,TNF-α:P=0.010),and did not increase the incidence of major bleeding events (incidence of non-major bleeding events 9.43% vs 4.00%,P=0.273).Conclusion: Combined administration of ticagrelor and aspirin in antiplatelet therapy for the patients with AMI-PCI is effective and has good prognosis without increasing the risk of bleeding.
Welcome to PCAR! You are the number 103 reader of this article!
Please cite this article as:
ZHANG Jiangxia1,DING Yanhua1,LI Xianzhe2,LUO Yamin2,ZHANG Jing1,. Efficacy of dual anti-platelet therapy with ticagrelor and aspirin in the treatment of acute myocardial infarction patients undergoing percutaneous coronary intervention[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2019; 19(4): 259-262,294.
References:
1. LI Jiang,LIU Wenxian,ZHAO Yi’nan,et al.The effect of ticagrelor on platelet aggregation ratio in patients with clopidogrel resistance[J].Chin Gen Pract,2014,17(19):2231-2234.In Chinese with English abstract.
2. Wallentin L,Becker R C,Budaj A,et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes[J].New Eng J Med,2009,361(11):1045-1057.
3. ZHENG Shikang,REN Hui,SHU Juan.Comparison of therapeutic effects of clopidogrel and loading dose ticagrelor on aged patients with ST elevation myocardial infarction[J].Chin J Cardiovasc Rehabil Med,2017,26(2):189-192.In Chinese with English abstract.
4. Clavijo L C,Maya J,Carlson G,et al.Platelet inhibition with ticagrelor versus clopidogrel in Hispanic patients with stable coronary artery disease with or without diabetes mellitus[J].Cardiovasc Revasc Med,2015,16(8):450-454.
5. GONG Xiangyin.The clinical significance of the serum levels of IL-6,IL-8 and TNF-α in the patients with acute cerebral infarction(ACS)[J].Chron Pathematol J,2010,12(10):1240-1241.In Chinese with English abstract.
6. ZHAO Liyan.The effect of aspirin combined with ticagrelor on inflammatory cytokines in patients with unstable angina pectoris after percutaneous coronary intervention[J].Chin J Integr Med Cardio-/CerebroVasc Dis,2017,15(16):2002-2005.In Chinese.
7. LIU Rongjun,YANG Ruwen,LIU Ming.Detection and analysis of interleukins and C-reactive protein in patients with acute coronary syndrome[J].Lab Med Clin,2009,6(19):1678-1679.In Chinese.
8. ZHANG Bin,GAO Naijun,FENG Wanyu.Systematic evaluation on respective efficacy and safety of ticagrelor and clopidogrel used for post-PCI in patients with Chinese acute STEMI[J].Eval Anal Drug-use Hosp China,2017,17(8):1094-1096,1100.In Chinese with English abstract.
9. Interventional Cardiology Group of Cardiovascular Diseases Branch of Chinese Medical Association,Thrombosis Prevention Committee of Cardiovascular Physician Branch of Chinese Medical Association,Editorial Board of Chinese Journal of Cardiovascular Diseases.Chinese guidelines for percutaneous coronary intervention(2016)[J].Chin J Cardiol,2016,44(5):382-400.In Chinese.
10. MENG Haiyan,KOU Xuejun,ZHOU Guo,et al.Effects of low dose ticagrelor on platelet aggregation rate and bleeding in patients with acute coronary syndrome[J].Shandong Med J,2017,57(33):67-69.In Chinese.
11. JIA Haibo,DAI Jiannan,HOU Jingbo,et al.Effective anti-thrombotic therapy without stenting: intravascular optical coherence tomography-based management in plaque erosion(the EROSION study)[J].Eur Heart J,2017,38(11):792-800.
《药学服务与研究》杂志社 All Rights Reserved 网站备案号:鲁B2-20061008
·地址:上海市杨浦区长海路168号18号楼东三楼 邮政编码:200433
·联系电话(传真):86-21-65519829, 021-31162330
·电子邮件:PharmCR@vip.163.com
·技术支持:中国康网
管理员入口